BioStem Technologies (OTCMKTS:BSEM – Get Free Report) and HCW Biologics (NASDAQ:HCWB – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.
Insider & Institutional Ownership
3.0% of HCW Biologics shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares BioStem Technologies and HCW Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioStem Technologies | N/A | N/A | N/A |
| HCW Biologics | -83.03% | -262.33% | -34.90% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioStem Technologies | $292.21 million | 0.19 | -$28.56 million | ($1.60) | -1.94 |
| HCW Biologics | $50,000.00 | 62.74 | -$7.96 million | ($27.60) | -0.06 |
HCW Biologics has lower revenue, but higher earnings than BioStem Technologies. BioStem Technologies is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for BioStem Technologies and HCW Biologics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioStem Technologies | 0 | 1 | 0 | 1 | 3.00 |
| HCW Biologics | 1 | 0 | 1 | 0 | 2.00 |
BioStem Technologies presently has a consensus target price of $9.00, suggesting a potential upside of 190.32%. HCW Biologics has a consensus target price of $30.00, suggesting a potential upside of 1,659.53%. Given HCW Biologics’ higher probable upside, analysts plainly believe HCW Biologics is more favorable than BioStem Technologies.
Volatility and Risk
BioStem Technologies has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500.
Summary
HCW Biologics beats BioStem Technologies on 8 of the 15 factors compared between the two stocks.
About BioStem Technologies
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
About HCW Biologics
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Receive News & Ratings for BioStem Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioStem Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
